carmustine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

37 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carmustine / Generic mfg.
ACTRN12623000620628: NHL38 Epco-Sandwich: A trial to assess the safety and efficacy of Epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and Epcoritamab consolidation in patients with relapsed large B-cell lymphoma.

Not yet recruiting
2
39
 
Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG)
Diffuse Large B-Cell Lymphoma
 
 
ACTRN12606000083594: Safety and efficacy trial of whey growth factor extract for oral mucositis

Not yet recruiting
2
60
 
TGR Biosciences, TGR Biosciences
Oral mucositis in lymphoma patients
 
 
ACTRN12613000339752: A Single Centre Phase II Study Of Haematopoietic Stem Cell Transplantation (HSCT) for Severe Auto-Immune Diseases.

Recruiting
2
150
 
St Vincent's Hospital, Sydney, St Vincent's Hospital, Sydney
Auto Immune disorders
 
 
ACTRN12616000151437: A Phase II study: Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis .

Recruiting
2
20
 
Austin Health, Austin Health
Relapsing Remitting Multiple Sclerosis
 
 
ACTRN12622000536763: Autologous Stem Cell Transplant in Multiple Sclerosis

Recruiting
2
30
 
St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney
Multiple Sclerosis
 
 
2004-004349-16: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high dose BEAM followed by autologous stem cell transplantation (ASCT)

Ongoing
2
75
Europe
Ibritumomab tiuxetan, Yttrium-90, CARMUSTINE, Mabthera, Aracytine, Alkeran, Etoposide, Ro45 2994, Kit for radiopharmaceutical preparation, Radiopharmaceutical precursor, Powder and solvent for solution for injection, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Solution for infusion, Zevalin, Ytracis, BCNU, Mabthera100mg, Mabthera500mg, Aracytine, Alkeran, VP16
GELA Group
Low grade B-cell lymphoma CD20 positive:-Marginal zone-Lymphocytic-Follicular
 
 
2009-012432-32: Et randomiseret fase ll studie af primær kemoterapi med højdosis Methotrexat og højdosis Cytarabin med eller uden thiotepa og med eller uden Rituximab efterfulgt af strålebehandling eller højdosis kemoterapi med autolog stamcelletransplantation hos immunkompetente patienter med nydiagnosticeret primært CNS-lymfom.

Ongoing
2
200
Europe, RoW
Methotrexate, Cytarabine, Rituximab, Thiotepa, Carmustine, Solution for injection, Concentrate for solution for infusion, Powder for injection, Powder and solvent for solution for infusion, Methotrexate, Cytarabine, Mabthera, Thiotepa, Carmustine
IELSG-International Extranodal Lymphoma Study Group, University Medical Center Freiburg Dept. Klinikum Stuttgart, Stuttgart Cancer Center, University Hospital Southampton NHS Foundation Trust, International Extranodal Lymphoma Srudy Group IELSG
Newly diagnosed Primary CNS Lymphoma, Diseases [C] - Cancer [C04]
 
 
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

Ongoing
2
222
Europe
PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN
Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA)
CD20+ diffuse large B-cell lymphoma
 
 
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Active, not recruiting
2
140
Europe
cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2
Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories
Primary Central Nervous System Lymphoma
05/16
05/26
LYMA-101, NCT02896582 / 2016-000548-33: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Checkmark From LyMa-101 trial in combination with high-dose cytarabine induction in 1L mantle cell lymphoma
Sep 2020 - Sep 2020: From LyMa-101 trial in combination with high-dose cytarabine induction in 1L mantle cell lymphoma
Active, not recruiting
2
86
Europe
Obinutuzumab, GA, GA101, Dexamethasone, Aracytine, Cytarabine, Cisplatinum, Etoposide, Melphalan, Carmustine, BiCNU, BCNU
The Lymphoma Academic Research Organisation
Mantle Cell Lymphoma
03/19
03/25
NCT02329080: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Active, not recruiting
2
76
Europe, RoW
Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B-cell Lymphoma
08/19
12/23
NCT03629873: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

Active, not recruiting
2
69
RoW
Chidamide, Carmustine, Etoposide, Cytarabine, Cyclophosphamide, Autologous hematopoeitic stem cell transplantation
The First Affiliated Hospital with Nanjing Medical University
Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma, Double-hit Lymphoma
12/21
12/21
ACTRN12619000990123: A study to look at the safety and efficacy of Acalabrutinib and Rituximab followed by chemo with or without Autologous stem cell transplant (ASCT) and maintenance Acalabrutinib and Rituximab in fit patients with previously untreated mantle cell lymphoma.

Active, not recruiting
2
44
 
Australasian Leukaemia and Lymphoma Group, Acerta
Mantle cell Lymphoma
 
 
NCT05088226: Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Recruiting
2
50
RoW
Ruxolitinib combined with Chidamide., Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide
Chinese PLA General Hospital
Peripheral Blood Stem Cell Transplantation
06/22
06/23
NCT05425654: RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Recruiting
2
30
RoW
Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide, Busulfan, Carmustine, and Cyclophosphamide
National Research Center for Hematology, Russia
Primary CNS Lymphoma
05/23
05/26
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
EATL-001, NCT03217643 / 2016-002782-57: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.

Completed
2
14
Europe
Brentuximab Vedotin
Imagine Institute, Takeda
Enteropathy Associated T-cell Lymphoma
11/22
05/23
NCT05398224: R-MTX-zanbrutinib in Secondary CNS Lymphoma

Recruiting
2
45
RoW
Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Peking University
Secondary Central Nervous System Lymphoma
02/24
05/24
ChiCTR2200055554: A Observation Study of Thiotepa in Thetreatment of Primary Central Nervous System Lymphoma (PCNSL)

Recruiting
2
32
 
RM+TT ;R-CHOP + R + Thiotepa+ MTX regimen ;IR + Thiotepa (BTKi + rituximab + Thiotepa） ;carmustine + Thiotepa pretreatment
The Second Hospital of Lanzhou University; Lanzhou University Second Hospital, self-raised
Primary central nervous system lymphoma/Central?high?risk?of?diffuse?large?B-cell?lymphoma
 
 
BEAM, NCT03570983: A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan () as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Recruiting
2
100
US
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Swedish Medical Center
Multiple Myeloma
06/24
12/24
Chi-BEAM, NCT05367856: Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma

Recruiting
2
23
RoW
Chidamide combined with BEAM
Ruijin Hospital
T Cell Lymphoma
06/24
06/25
hSTAR GBM, NCT05052957: (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Recruiting
2
16
US
P140K-MGMT, O6-benzylguanine, BG, Photon Based Radiotherapy, temozolomide, TMZ, Filgrastim, G-CSF,Granulocyte-Colony Stimulating Factor, carmustine, BCNU,bis-chloronitrosourea
Leland Metheny, National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
06/24
12/24
NCT01908777: A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Active, not recruiting
2
47
US
High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin, Carmustine, VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran), Romidepsin (Istodax)
Memorial Sloan Kettering Cancer Center, University of Washington, Weill Medical College of Cornell University, H. Lee Moffitt Cancer Center and Research Institute
T Cell Non-Hodgkin Lymphoma
07/24
07/24
NCT06377540: MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Not yet recruiting
2
28
NA
Pembrolizumab, Keytruda; MK-3475, Autologous stem cell transplant, ASCT, Carmustine, BCNU, BICNU, Etoposide, Cytarabine, Ara-C, Melphalan
Masonic Cancer Center, University of Minnesota
Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
09/26
09/27
NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
59
US
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
10/24
10/24
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
NCT04728633: Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Recruiting
2
28
US
Carmustine, 1,3-Bis(2-chloroethyl)-1-nitrosourea, 1,3-Bis(beta-chloroethyl)-1-nitrosourea, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, WR-139021, SRI 1720, SK 27702, Nitrumon, Nitrourean, N,N''-Bis(2-chloroethyl)-N-nitrosourea, FDA 0345, Carmustinum, Carmustin, Ethiodized Oil, Lipiodol, Iodized Oil, Ethiodol, ETHIODIZED OIL,, 8008-53-5, Transarterial Chemoembolization, TACE, Medical Device Usage and Evaluation
Thomas Jefferson University
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
06/25
03/26
NCT03125642: Auto Stem Cell Transplant for Lymphoma Patients

Recruiting
2
150
US
Etoposide, VP-16, BCNU, Carmustine, AraC, Cytarabine, cytosine arabinoside, Cytosar-U, Depocyt, Melphalan, Alkeran, Peripheral blood stem cell transplantation, PBSC, G-CSF, filgrastim, Cyclophosphamide, Cytoxan, Total Body Irradiation, TBI
Masonic Cancer Center, University of Minnesota
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
09/25
04/26
CALGB 51101, NCT01511562: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Active, not recruiting
2
113
US
carmustine, cytarabine, etoposide, thiotepa, stem cell transplant, G-CSF
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lymphoma
10/26
 
NCT04871607: Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting
2
33
US
Basiliximab, SDZ-CHI-621, Simulect, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Genetically Engineered Hematopoietic Stem Progenitor Cells, Genetically Engineered HSPCs, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Yttrium Y 90 Basiliximab, 90Y Basiliximab, Yttrium Y 90-DOTA-Basiliximab
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
10/27
10/27
NCT00716066: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Active, not recruiting
2
53
US
Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, 154-93-8, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, 147-94-4, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, 33419-42-0, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, 148-82-3, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, 53-03-2, Syngeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Center
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
01/25
01/30
NCT02797470: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting
1/2
11
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation
AIDS Malignancy Consortium, National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
05/21
06/25
OSU-17225, NCT03583424: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Active, not recruiting
1/2
19
US
Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, stem cell transplantation, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Ohio State University Comprehensive Cancer Center
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Indolent Non-Hodgkin Lymphoma
12/22
12/22
XPORT-GBM-029, NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated
1/2
74
Canada, US
Selinexor, KPT-330, XPOVIO, Temozolomide (TMZ), Temodar, Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Karyopharm Therapeutics Inc
Glioblastoma Multiforme
07/23
07/23
NCT04582604: Ruxolitinib and Decitabine for High Risk Hematological Malignancies

Recruiting
1/2
60
RoW
modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine, Ruxolitinib and Decitabine
Chinese PLA General Hospital
Peripheral Blood Stem Cell Transplantation
09/23
09/25
NCT05075681: Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

Recruiting
1/2
50
RoW
Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide, Ruxolitinib and Chidamide
Chinese PLA General Hospital
Peripheral Blood Stem Cell Transplantation
06/24
06/25
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25

Download Options